ATE296106T1 - Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc - Google Patents

Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc

Info

Publication number
ATE296106T1
ATE296106T1 AT00912310T AT00912310T ATE296106T1 AT E296106 T1 ATE296106 T1 AT E296106T1 AT 00912310 T AT00912310 T AT 00912310T AT 00912310 T AT00912310 T AT 00912310T AT E296106 T1 ATE296106 T1 AT E296106T1
Authority
AT
Austria
Prior art keywords
dna
mcc
composition
cancer cells
prostate cancer
Prior art date
Application number
AT00912310T
Other languages
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of ATE296106T1 publication Critical patent/ATE296106T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00912310T 1999-04-01 2000-03-30 Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc ATE296106T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12745199P 1999-04-01 1999-04-01
PCT/CA2000/000342 WO2000059518A2 (en) 1999-04-01 2000-03-30 Composition and method for inducing apoptosis in prostate cancer cells

Publications (1)

Publication Number Publication Date
ATE296106T1 true ATE296106T1 (de) 2005-06-15

Family

ID=22430191

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00912310T ATE296106T1 (de) 1999-04-01 2000-03-30 Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc

Country Status (10)

Country Link
EP (1) EP1165106B8 (de)
JP (1) JP2002541114A (de)
AT (1) ATE296106T1 (de)
AU (1) AU780909B2 (de)
CA (1) CA2366090C (de)
CY (1) CY1107455T1 (de)
DE (1) DE60020352T2 (de)
ES (1) ES2238996T3 (de)
PT (1) PT1165106E (de)
WO (1) WO2000059518A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4488626B2 (ja) * 1998-12-04 2010-06-23 バイオニケ ライフ サイエンシーズ インコーポレイテッド 炎症の治療法
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE227996T1 (de) * 1997-08-05 2002-12-15 Bioniche Life Sciences Inc Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod

Also Published As

Publication number Publication date
CA2366090C (en) 2011-05-24
WO2000059518A2 (en) 2000-10-12
JP2002541114A (ja) 2002-12-03
EP1165106B1 (de) 2005-05-25
ES2238996T3 (es) 2005-09-16
DE60020352T2 (de) 2005-10-20
CY1107455T1 (el) 2012-12-19
EP1165106A2 (de) 2002-01-02
PT1165106E (pt) 2005-10-31
CA2366090A1 (en) 2000-10-12
EP1165106B8 (de) 2005-07-27
WO2000059518A3 (en) 2001-02-01
AU3413500A (en) 2000-10-23
AU780909B2 (en) 2005-04-21
DE60020352D1 (de) 2005-06-30

Similar Documents

Publication Publication Date Title
MY121548A (en) Compounds and methods for the treatment of cancer
DK1280552T3 (da) Fremgangsmåde til behandling af hudcancer ved anvendelse af præparater der omfatter en endothelin B-receptor-inhibitor
BR9709015A (pt) Quinolina carboxamidas como inbidores de tnf e como inbidores de pde-iv
DE60027719D1 (de) Krebstherapie
ATE324877T1 (de) Behandlung von metastatischer krankheit
ID26620A (id) Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi
WO2004064727A3 (en) Method of cancer treatment using hdac inhibitors
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DK47089A (da) Middel med oedelaeggende virkning paa maligne tumorer, fremgangsmaade til fremstilling af saadanne midler og anvendelse af disse til terapeutisk behandling af cancer
EA200300934A1 (ru) Агенты и способы, предназначенные для лечения опухолевых заболеваний
PL374675A1 (en) Use of urease for inhibiting cancer cell growth
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
PT1051187E (pt) Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt)
ATE296106T1 (de) Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
WO2004013313A3 (en) Antisense nucleic acids
ATE243522T1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
EA200601630A1 (ru) Ниосома, имеющая внедрённый в неё маталлопорфириновый комплекс, способ её получения и лекарственное средство с её использованием
DK0579791T3 (da) Cellulær sammensætning til behandling af menneske- og dyreorganismer
ATE290390T1 (de) Behandlung des harnblasenkrebses durch mycobacterium phlei zellwand
MXPA05009715A (es) Anticuerpo contra antigeno especifico de tumor como objetivo.
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
Joshi et al. Comparison of three mammalian cell-lines with respect to their sensitivities to hyperthermia, γ-rays and UV-radiation
Gevorkyan et al. Anticancer efficacy of hydroxyethylthiamine diphosphate in vivo
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165106

Country of ref document: EP